Zacks Research Issues Positive Estimate for NKTR Earnings
Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Analysts at Zacks Research increased their Q2 2025 earnings estimates for shares of Nektar Therapeutics in a research report issued on Wednesday, June 18th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will earn ($0.19) per share for the quarter, up from their previous estimate […]
Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Analysts at Zacks Research increased their Q2 2025 earnings estimates for shares of Nektar Therapeutics in a research report issued on Wednesday, June 18th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will earn ($0.19) per share for the quarter, up from their previous estimate […]
